|本期目录/Table of Contents|

[1]谢 芳,汪茂荣,张 馨,等.替比夫定联合胸腺素-α1与单用替比夫定治疗HBeAg阳性慢性乙型肝炎的比较研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(04):342-345，352.[doi:10.3969/j.issn.1672-271X.2015.04.002]
　XIE Fang,WANG Mao-rong,ZHANG Xin,et al.Telbivudine (LDT) compared with LDT plus thymosin-α1 for treatment of HBeAg-positive chronic hepatitis B[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):342-345，352.[doi:10.3969/j.issn.1672-271X.2015.04.002]
点击复制

替比夫定联合胸腺素-α1与单用替比夫定治疗HBeAg阳性慢性乙型肝炎的比较研究()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第17卷
期数:
2015年04期
页码:
342-345，352
栏目:
出版日期:
2015-07-20

文章信息/Info

Title:
Telbivudine (LDT) compared with LDT plus thymosin-α1 for treatment of HBeAg-positive chronic hepatitis B
作者:
谢 芳1; 汪茂荣1; 张 馨1; 杨志国1; 耿家宝1; 储旭东2; 浦永兰3; 李 明4
1.210002 江苏南京，解放军81医院全军肝病中心；2.224000 江苏盐城，东台市人民医院传染科；3.215400 江苏苏州，太仓市第一人民医院传染科；4.215007 江苏苏州，苏州市第五人民医院传染科
Author(s):
XIE Fang1;  WANG Mao-rong1;  ZHANG Xin1;  YANG Zhi-guo1;  GENG Jia-bao1;  CHU Xu-dong2;  PU Yong-lan3;  LI Ming4.
1.Institute for Hepatology， 81 Hospital of PLA， Nanjing， Jiangsu 210002， China； 2.Department of Infectious Disease， Dongtai Peoples Hospital， Yancheng， Jiangsu 224000， China； 3.Department of Infectious Disease， Taicang First Peoples Hospital， Suzhou， Jiangsu 215400， China； 4.Department of Infectious Disease， Suzhou No.5 Hospital， Suzhou， Jiangsu 215007， China
关键词:
替比夫定; 胸腺素-α1; 联合治疗; HBeAg阳性慢性乙型肝炎; HBeAg血清学转换
Keywords:
telbivudine;  thymosin-α1;  combination therapy;  HBeAg-positive chronic hepatitis B;  HBeAg seroconversion
分类号:
R512.62
DOI:
10.3969/j.issn.1672-271X.2015.04.002
文献标志码:
A
摘要:
目的 探讨替比夫定联合胸腺素-α1治疗HBeAg阳性慢性乙型肝炎的疗效及安全性。方法 106例HBeAg阳性的慢性乙型肝炎患者随机分为替比夫定联合胸腺素-α1治疗组(联合用药组)52例和单用替比夫定治疗组(单用药组)54例，观察两组治疗24周、48周时ALT复常率、HBV-DNA转阴率、HBeAg转阴率、HBeAg血清学转换率及不良反应。结果 治疗24周时，联合用药组和单用药组HBV-DNA转阴率分别为75.0%(39/52)、77.8%(42/54)，差异无统计学意义(P>0.05)；联合用药组HBeAg转阴率为26.9%(14/52)，HBeAg血清学转换率为25.0%(13/52)与单用药组的18.5%(10/54)、16.7%(9/54)相比较，差异均无统计学意义(P>0.05)。治疗48周时，两组HBV-DNA转阴率比较差异无统计学意义［88.5%(46/52)、79.6%(43/54)，P>0.05］；联合用药组的HBeAg转阴率为38.5%(20/52)，HBeAg血清学转换率为36.5%(19/52)，与单用药组的20.4%(11/54)和18.5%(10/54)相比较，差异有统计学意义(P<0.05)。治疗过程中，两组均未发生严重不良反应。结论 替比夫定联合胸腺素-α1治疗HBeAg阳性慢性乙型肝炎疗效优于单用替比夫定，是安全有效的治疗方法。
Abstract:
Objective To investigate the efficacy and safty of LDT plus thymosin-α1 combination therapy in HBeAg positive chronic hepatitis B(CHB)patients. Methods One hundred and six patients with chronic hepatitis B were randomly divided into LDT plus thymosin-α1 group 52 cases(combination therapy group)and LDT group 54 cases(monotherapy group). The rate of ALT normalization, HBV DNA undetectable, HBeAg loss, HBeAg seroconversion and drug related adverse events were observed at week 24 and 48. Results At week 24, the rate of HBV DNA undetectable was 75.0%(39/52) in the combination therapy group versus 77.8%(42/54) in the monotherapy group(P﹥0.05); 26.9%(14/52) of patients got HBeAg lost, 25.0%(13/52) of patients got HBeAg seroconversed in combination therapy group. When compared with that of 18.5%(10/54), 16.7%(9/54) in monotherapy group, respectively(P>0.05). At week 48, the rate of HBV DNA undetectable was 88.5%(46/52) and 79.6%(43/54), respectively in the combination therapy group and monotherapy group(P﹥0.05). 38.5%(20/52) of patients got HBeAg lost, 36.5%(19/52) of patients got HBeAg seroconversed in combination therapy group. When compared with that of 20.4%(11/54), 18.5%(10/54) in monotherapy group,respectively(P<0.05). No reverse adverse reaction was happened in both groups. Conclusion The combination of telbivudine plus Thymosin-α1 provided significant efficacy and higher safety than telbivudine monotherapy in HBeAg positive chronic hepatitis B(CHB)patients, which is a better combination therapy.

参考文献/References:

［1］Liaw YF，Gane E，Leung N，et al.2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B［J］.Gastroenterology，2009，136(2):486-495.
［2］Gane EJ，Wang Y，Liaw YF，ea tal.Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B［J］.Liver Int，2011，31(5):676-684.
［3］Lv GC，Ma WJ，Ying LJ，et al.Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels［J］.World J Gastroenterol，2010，16(32):4095-4099.
［4］中华医学会肝病学分会、中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)［J］.中华肝脏病杂志，2011，19(1):13-24.
［5］Ocama P,Opio CK,Lee WM.Hepatitis B virus infection:current status［J］.Am J Med,2005,118(12):1413.
［6］Lai CL，Ratziu V，Yuen MF，et al.Viral hepatitis B［J］.Lancet，2003，362(9041):2089-2094.
［7］Farrell GC，Teoh NC.Management of chronic hepatitis B virus infection:a new era of disease control［J］.Intern Med J，2006，36(2):100-113.
［8］Merican I，Guan R，Amarapuka D，et al.Chronic hepatitis B virus infection in Asian countries［J］.J Gastroenterol Hepatol，2000，15(12):1356-1361.
［9］Ganem D，Prince AM.Hepatitis B virus infection-natural history and clinical consequences［J］.N Engl J Med，2004，350(11):1118-1129.
［10］Tang CM，Yau TO，Yu J.Management of chronic hepatitis B infection:current treatment guidelines，challenges，and new developments［J］.World J Gastroenterol，2014，20(20):6262-6278.
［11］Liang X，Bi S，Yang W，et al.Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination［J］.Vaccine，2009，27(47):6550-6557.
［12］Liang X，Bi S，Yang W，et al.Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China［J］.J Infect Dis，2009，200(1):39-47.
［13］Lu FM，Zhuang H.Management of hepatitis B in China［J］.Chin Med J(Engl)，2009，122(1):3-4.
［14］Jiang YF，Ma ZH，Zhao PW，et al.Effect of thymosin-α(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B［J］.J Int Med Res，2010，38(6):2053-2062.
［15］Lim SG，Wai CT，Lee YM，et al.A randomized，placebo-controlled trial of thymosin-alphal and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B［J］.Antivir Ther，2006，11(2):245-253.
［16］You J，Zhuang L，Cheng HY，et al.A randomized，controlled，clinical study of thymosin alpha-1 versus interferon-alpha in patients with chronic hepatitis B lacking HBeAg in China［J］.J Chin Med Assoc，2005，68(2):65-72.
［17］毛海鹰，石统东.干扰素联合胸腺肽α1治疗e抗原阳性慢性乙型肝炎的荟萃分析［J］.中华肝脏病杂志，2011，19(1):29-33.
［18］Chan HL，Tang JL，Tam W，et al.The efficacy of thymosin in the treatment of chronic hepatitis B virus infection:a meta-analysis［J］.Aliment Pharmacol Ther，2001，15(12):1899-1905.
［19］Piratvisuth T.Reviews for APASL guidelines:immunomodulator therapy of chronic hepatitis B［J］.Hepatol Int，2008，2(2):140-146.
［20］曹 辉，殷萍萍，王 坚，等.抗乙型肝炎病毒核苷(酸)类似物使用情况分析［J］.医学研究生学报，2013，26(9):963-965.
［21］陈 勇，胡毓安.乙型肝炎病毒表面大蛋白的研究进展［J］.东南国防医药，2013，15(4):381-383.

相似文献/References:

[1]张骏飞,郭远,陈从新,等.替比夫定治疗慢加亚急性乙型肝炎肝衰竭的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2016,18(02):131.[doi:10.3969/j.issn.1672-271X.2016.02.007]
　ZHANG Jun-fei,GUO Yuan,CHEN Cong-xin,et al.A study on the treatment effect of telbivudine on hepatitis B patients with acute on chronic liver failure[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(04):131.[doi:10.3969/j.issn.1672-271X.2016.02.007]

备注/Memo

备注/Memo:
“十二五”国家科技重大专项(2012ZX10002003-005)
更新日期/Last Update: 2015-07-20